Related references
Note: Only part of the references are listed.Design, synthesis, and anticancer activity of novel 4-thiazolidinone-phenylaminopyrimidine hybrids
Asli Ture et al.
MOLECULAR DIVERSITY (2021)
Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents
Ting Guo et al.
CHEMMEDCHEM (2021)
Human variability in polymorphic CYP2D6 metabolism: Implications for the risk assessment of chemicals in food and emerging designer drugs
K. Darney et al.
ENVIRONMENT INTERNATIONAL (2021)
Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations
Antonio Passaro et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Progress of exosomes in the diagnosis and treatment of lung cancer
Kanghong Xu et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models
Sitanshu S. Singh et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations
Edward S. Kim et al.
FUTURE ONCOLOGY (2021)
Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines
Marian W. Aziz et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)
Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib
Han Han et al.
CANCER RESEARCH (2021)
Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumour cells
Yan Zhang et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2021)
Development of 3-methyl/3-(morpholinomethyl)benzofuran derivatives as novel antitumor agents towards non-small cell lung cancer cells
Mohammad M. Al-Sanea et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2021)
Synthesis, biological evaluation and molecular modeling study of [1,2,4]-Triazolo[4,3-c]quinazolines: New class of EGFR-TK inhibitors
Wafaa A. Ewes et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2020)
Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents
Cristina Minnelli et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2020)
The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)
Ping-Chih Hsu et al.
CANCERS (2020)
A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy
Adileh Ayati et al.
BIOORGANIC CHEMISTRY (2020)
Squaramides as Bioisosteres in Contemporary Drug Design
Kylie A. Agnew-Francis et al.
CHEMICAL REVIEWS (2020)
Design, Synthesis, and Biological Evaluation of Covalent Inhibitors of Focal Adhesion Kinase (FAK) against Human Malignant Glioblastoma
Bo Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer
Li Li et al.
CANCER LETTERS (2019)
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma
Christopher R. M. Asquith et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
Ciric To et al.
CANCER DISCOVERY (2019)
Targeting an EGFR Water Network with 4-Anilinoquin(az)oline Inhibitors for Chordoma
Christopher R. M. Asquith et al.
CHEMMEDCHEM (2019)
Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers
Aiten M. Soliman et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2019)
Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
Nicolas Girard
FUTURE ONCOLOGY (2018)
Synthesis and antimicrobial evaluation of 3-(4-arylthieno[2,3-d]pyrimidin-2-yl)-2H-chromen-2-ones
Sergiy V. Vlasov et al.
HETEROCYCLIC COMMUNICATIONS (2018)
KRAS-Mutant non-small cell lung cancer: From biology to therapy
Irene Ferrer et al.
LUNG CANCER (2018)
How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors
Sandra N. Milik et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment
Zhishan Cui et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Understanding and targeting resistance mechanisms in NSCLC
Julia Rotow et al.
NATURE REVIEWS CANCER (2017)
Kinase inhibitors and monoclonal antibodies in oncology: clinical implications
Helen Gharwan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Computational methods in drug discovery
Sumudu P. Leelananda et al.
BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY (2016)
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
D. A. Fennell et al.
CANCER TREATMENT REVIEWS (2016)
Lung cancer: Biology and treatment options
Hassan Lemjabbar-Alaoui et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2015)
Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer
Hye-Young Min et al.
MOLECULAR CANCER (2015)
Metastatic sites and survival in lung cancer
M. Riihimaeki et al.
LUNG CANCER (2014)
Cell Lines Expressing Recombinant Transmembrane Domain-Activated Receptor Kinases as Tools for Drug Discovery
Holger Weber et al.
JOURNAL OF BIOMOLECULAR SCREENING (2014)
BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives
Jing Cui et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Src Mediates Cigarette Smoke-Induced Resistance to Tyrosine Kinase Inhibitors in NSCLC Cells
Simone Filosto et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Synthesis of some 3-substituted amino-4,5-tetramethylene thieno[2,3-d] [1,2,3]-triazin-4(3(H)under-bar)-ones as potential antimicrobial agents
Janardhanan Saravanan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2010)
Design and Synthesis of Novel 2-Phenylaminopyrimidine (PAP) Derivatives and Their Antiproliferative Effects in Human Chronic Myeloid Leukemia Cells
Sheng Chang et al.
MOLECULES (2009)
Evaluation of phenylaminopyrimidines as antifungal protein kinase inhibitors
C Pillonel
PEST MANAGEMENT SCIENCE (2005)
ST1571 (Gleevec (TM)) as a paradigm for cancer therapy
BJ Druker
TRENDS IN MOLECULAR MEDICINE (2002)
Share Paper
